# Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

> **NCT03775525** · PHASE1 · UNKNOWN · sponsor: **Genzada Pharmaceuticals USA, Inc.** · enrollment: 127 (estimated)

## Conditions studied

- Advanced Cancer
- Gastric Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer Metastatic
- Colo-rectal Cancer
- Solid Tumor
- Solid Carcinoma
- Solid Carcinoma of Stomach
- Cancer of Stomach
- Lymphoma
- Sarcoma
- Cutaneous T Cell Lymphoma
- Head and Neck Squamous Cell Carcinoma
- Basal Cell Carcinoma
- Cutaneous T-cell Lymphoma
- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** GZ17-6.02
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03775525
- **Lead sponsor:** Genzada Pharmaceuticals USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2023-05
- **Final completion:** 2023-12
- **Target enrollment:** 127 (ESTIMATED)
- **Last updated:** 2022-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03775525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03775525, "Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03775525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*